Selected research
Industry Research
Systemic Sclerosis Drug Industry Research Report 2026
Market perspective
The global Systemic Sclerosis Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Systemic Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Systemic Sclerosis Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Systemic Sclerosis Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Systemic Sclerosis Drug include GlaxoSmithKline Plc, Bayer AG, GenKyoTex S.A., Fibrocell Science, Inc., F. Hoffmann-La Roche Ltd., Digna Biotech, S.L., Daval International Limited, CSL Limited and Corbus pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Systemic Sclerosis Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Systemic Sclerosis Drug Market by Company
GlaxoSmithKline Plc
Bayer AG
GenKyoTex S.A.
Fibrocell Science, Inc.
F. Hoffmann-La Roche Ltd.
Digna Biotech, S.L.
Daval International Limited
CSL Limited
Corbus pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
BiOrion Technologies B.V.
BioLineRx, Ltd.
arGentis Pharmaceuticals, LLC
Angion Biomedica Corp.
Allergan Plc
Systemic Sclerosis Drug Segment by Type
ARG-201
BL-1110
BOT-191
C-82
Belimumab
Others
Systemic Sclerosis Drug Segment by Application
Clinic
Hospital
ASCs
Others
Systemic Sclerosis Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Systemic Sclerosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Systemic Sclerosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Systemic Sclerosis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Systemic Sclerosis Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Systemic Sclerosis Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Systemic Sclerosis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ARG-201
- BL-1110
- BOT-191
- C-82
- Belimumab
- Others
Applications
- Clinic
- Hospital
- ASCs
- Others
Companies covered
- GlaxoSmithKline Plc
- Bayer AG
- GenKyoTex S.A.
- Fibrocell Science, Inc.
- F. Hoffmann-La Roche Ltd.
- Digna Biotech, S.L.
- Daval International Limited
- CSL Limited
- Corbus pharmaceuticals, Inc.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim GmbH
- BiOrion Technologies B.V.
- BioLineRx, Ltd.
- arGentis Pharmaceuticals, LLC
- Angion Biomedica Corp.
- Allergan Plc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Systemic Sclerosis Drug Market Size (2021-2032)
- 2.2.2 Global Systemic Sclerosis Drug Sales (2021-2032)
- 2.2.3 Global Systemic Sclerosis Drug Market Average Price (2021-2032)
- 2.3 Systemic Sclerosis Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 ARG-201
- 2.3.3 BL-1110
- 2.3.4 BOT-191
- 2.3.5 C-82
- 2.3.6 Belimumab
- 2.3.7 Others
- 2.4 Systemic Sclerosis Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 ASCs
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Systemic Sclerosis Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Systemic Sclerosis Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Systemic Sclerosis Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Systemic Sclerosis Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Systemic Sclerosis Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Systemic Sclerosis Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Systemic Sclerosis Drug, Product Type & Application
- 3.8 Global Manufacturers of Systemic Sclerosis Drug, Established Date
- 3.9 Global Systemic Sclerosis Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GlaxoSmithKline Plc
- 4.1.1 GlaxoSmithKline Plc Company Information
- 4.1.2 GlaxoSmithKline Plc Business Overview
- 4.1.3 GlaxoSmithKline Plc Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GlaxoSmithKline Plc Systemic Sclerosis Drug Product Portfolio
- 4.1.5 GlaxoSmithKline Plc Recent Developments
- 4.2 Bayer AG
- 4.2.1 Bayer AG Company Information
- 4.2.2 Bayer AG Business Overview
- 4.2.3 Bayer AG Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bayer AG Systemic Sclerosis Drug Product Portfolio
- 4.2.5 Bayer AG Recent Developments
- 4.3 GenKyoTex S.A.
- 4.3.1 GenKyoTex S.A. Company Information
- 4.3.2 GenKyoTex S.A. Business Overview
- 4.3.3 GenKyoTex S.A. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GenKyoTex S.A. Systemic Sclerosis Drug Product Portfolio
- 4.3.5 GenKyoTex S.A. Recent Developments
- 4.4 Fibrocell Science, Inc.
- 4.4.1 Fibrocell Science, Inc. Company Information
- 4.4.2 Fibrocell Science, Inc. Business Overview
- 4.4.3 Fibrocell Science, Inc. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Fibrocell Science, Inc. Systemic Sclerosis Drug Product Portfolio
- 4.4.5 Fibrocell Science, Inc. Recent Developments
- 4.5 F. Hoffmann-La Roche Ltd.
- 4.5.1 F. Hoffmann-La Roche Ltd. Company Information
- 4.5.2 F. Hoffmann-La Roche Ltd. Business Overview
- 4.5.3 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Product Portfolio
- 4.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 4.6 Digna Biotech, S.L.
- 4.6.1 Digna Biotech, S.L. Company Information
- 4.6.2 Digna Biotech, S.L. Business Overview
- 4.6.3 Digna Biotech, S.L. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Digna Biotech, S.L. Systemic Sclerosis Drug Product Portfolio
- 4.6.5 Digna Biotech, S.L. Recent Developments
- 4.7 Daval International Limited
- 4.7.1 Daval International Limited Company Information
- 4.7.2 Daval International Limited Business Overview
- 4.7.3 Daval International Limited Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Daval International Limited Systemic Sclerosis Drug Product Portfolio
- 4.7.5 Daval International Limited Recent Developments
- 4.8 CSL Limited
- 4.8.1 CSL Limited Company Information
- 4.8.2 CSL Limited Business Overview
- 4.8.3 CSL Limited Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 CSL Limited Systemic Sclerosis Drug Product Portfolio
- 4.8.5 CSL Limited Recent Developments
- 4.9 Corbus pharmaceuticals, Inc.
- 4.9.1 Corbus pharmaceuticals, Inc. Company Information
- 4.9.2 Corbus pharmaceuticals, Inc. Business Overview
- 4.9.3 Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Product Portfolio
- 4.9.5 Corbus pharmaceuticals, Inc. Recent Developments
- 4.10 Bristol-Myers Squibb Company
- 4.10.1 Bristol-Myers Squibb Company Company Information
- 4.10.2 Bristol-Myers Squibb Company Business Overview
- 4.10.3 Bristol-Myers Squibb Company Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bristol-Myers Squibb Company Systemic Sclerosis Drug Product Portfolio
- 4.10.5 Bristol-Myers Squibb Company Recent Developments
- 4.11 Boehringer Ingelheim GmbH
- 4.11.1 Boehringer Ingelheim GmbH Company Information
- 4.11.2 Boehringer Ingelheim GmbH Business Overview
- 4.11.3 Boehringer Ingelheim GmbH Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Boehringer Ingelheim GmbH Systemic Sclerosis Drug Product Portfolio
- 4.11.5 Boehringer Ingelheim GmbH Recent Developments
- 4.12 BiOrion Technologies B.V.
- 4.12.1 BiOrion Technologies B.V. Company Information
- 4.12.2 BiOrion Technologies B.V. Business Overview
- 4.12.3 BiOrion Technologies B.V. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 BiOrion Technologies B.V. Systemic Sclerosis Drug Product Portfolio
- 4.12.5 BiOrion Technologies B.V. Recent Developments
- 4.13 BioLineRx, Ltd.
- 4.13.1 BioLineRx, Ltd. Company Information
- 4.13.2 BioLineRx, Ltd. Business Overview
- 4.13.3 BioLineRx, Ltd. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 BioLineRx, Ltd. Systemic Sclerosis Drug Product Portfolio
- 4.13.5 BioLineRx, Ltd. Recent Developments
- 4.14 arGentis Pharmaceuticals, LLC
- 4.14.1 arGentis Pharmaceuticals, LLC Company Information
- 4.14.2 arGentis Pharmaceuticals, LLC Business Overview
- 4.14.3 arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Product Portfolio
- 4.14.5 arGentis Pharmaceuticals, LLC Recent Developments
- 4.15 Angion Biomedica Corp.
- 4.15.1 Angion Biomedica Corp. Company Information
- 4.15.2 Angion Biomedica Corp. Business Overview
- 4.15.3 Angion Biomedica Corp. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Angion Biomedica Corp. Systemic Sclerosis Drug Product Portfolio
- 4.15.5 Angion Biomedica Corp. Recent Developments
- 4.16 Allergan Plc
- 4.16.1 Allergan Plc Company Information
- 4.16.2 Allergan Plc Business Overview
- 4.16.3 Allergan Plc Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Allergan Plc Systemic Sclerosis Drug Product Portfolio
- 4.16.5 Allergan Plc Recent Developments
5 Global Systemic Sclerosis Drug Market Scenario by Region
- 5.1 Global Systemic Sclerosis Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Systemic Sclerosis Drug Sales by Region: 2021-2032
- 5.2.1 Global Systemic Sclerosis Drug Sales by Region: 2021-2026
- 5.2.2 Global Systemic Sclerosis Drug Sales by Region: 2027-2032
- 5.3 Global Systemic Sclerosis Drug Revenue by Region: 2021-2032
- 5.3.1 Global Systemic Sclerosis Drug Revenue by Region: 2021-2026
- 5.3.2 Global Systemic Sclerosis Drug Revenue by Region: 2027-2032
- 5.4 North America Systemic Sclerosis Drug Market Facts & Figures by Country
- 5.4.1 North America Systemic Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Systemic Sclerosis Drug Sales by Country (2021-2032)
- 5.4.3 North America Systemic Sclerosis Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Systemic Sclerosis Drug Market Facts & Figures by Country
- 5.5.1 Europe Systemic Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Systemic Sclerosis Drug Sales by Country (2021-2032)
- 5.5.3 Europe Systemic Sclerosis Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Systemic Sclerosis Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Systemic Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Systemic Sclerosis Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Systemic Sclerosis Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Systemic Sclerosis Drug Market Facts & Figures by Country
- 5.7.1 South America Systemic Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Systemic Sclerosis Drug Sales by Country (2021-2032)
- 5.7.3 South America Systemic Sclerosis Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Systemic Sclerosis Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Systemic Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Systemic Sclerosis Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Systemic Sclerosis Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Systemic Sclerosis Drug Sales by Type (2021-2032)
- 6.1.1 Global Systemic Sclerosis Drug Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Systemic Sclerosis Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Systemic Sclerosis Drug Revenue by Type (2021-2032)
- 6.2.1 Global Systemic Sclerosis Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Systemic Sclerosis Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Systemic Sclerosis Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Systemic Sclerosis Drug Sales by Application (2021-2032)
- 7.1.1 Global Systemic Sclerosis Drug Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Systemic Sclerosis Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Systemic Sclerosis Drug Revenue by Application (2021-2032)
- 7.2.1 Global Systemic Sclerosis Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Systemic Sclerosis Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Systemic Sclerosis Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Systemic Sclerosis Drug Value Chain Analysis
- 8.1.1 Systemic Sclerosis Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Systemic Sclerosis Drug Production Mode & Process
- 8.2 Systemic Sclerosis Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Systemic Sclerosis Drug Distributors
- 8.2.3 Systemic Sclerosis Drug Customers
9 Global Systemic Sclerosis Drug Analyzing Market Dynamics
- 9.1 Systemic Sclerosis Drug Industry Trends
- 9.2 Systemic Sclerosis Drug Industry Drivers
- 9.3 Systemic Sclerosis Drug Industry Opportunities and Challenges
- 9.4 Systemic Sclerosis Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst